Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lysosomal storage disorders
Pharma
Zevra lines up $150M from sale of PRV tied to Miplyffa approval
After receiving a priority review voucher from Miplyffa’s FDA approval in September, Zevra has locked in a deal to sell the voucher for $150 million.
Fraiser Kansteiner
Feb 27, 2025 9:58am
Zevra pegs Miplyffa as 'cornerstone' of Niemann-Pick treatment
Oct 4, 2024 6:45am
Zevra snags FDA approval for new lysosomal storage disorder med
Sep 20, 2024 1:54pm
DOJ probing BioMartin testing programs for Vimizim, Naglazyme
Feb 28, 2024 7:48am
